文献速递临床试验与 GCP流行病学与生物统计

局部或局部晚期前列腺癌术后辅助放疗与早期挽救放疗的系统综述与荟萃分析

Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data.
PubMed 文献 · Lancet · 2020-09-28

该研究采用前瞻性设计系统综述与荟萃分析,纳入3项随机对照试验共2153例接受根治性前列腺癌切除术的中高危局限或局部晚期患者,比较辅助放疗与早期挽救放疗。结论提示辅助放疗未改善无事件生存,早期挽救治疗可作为优先选择。

要点

  • 5年无事件生存率辅助放疗89%对早期挽救放疗88%,差异仅1个百分点。
  • 早期挽救策略可使部分患者避免放疗及其副作用。

核心结论

  • 辅助放疗未改善局部或局部晚期前列腺癌根治术后患者的无事件生存。
  • 在长期结局数据可用前,早期挽救治疗似乎是更可取的治疗策略。

研究设计与样本

  • 采用前瞻性自适应荟萃分析框架,在符合条件的试验进行中即启动系统综述。
  • 纳入3项随机对照试验,共2153例接受根治性前列腺切除术的中高危局限或局部晚期前列腺癌患者。
  • 中位随访60至78个月,最长随访132个月;所有试验评估为低偏倚风险。

主要发现

  • 5年无事件生存率辅助放疗为89%,早期挽救放疗为88%,差异1个百分点(95%CI -2至3)。

临床怎么用

  • 对于根治性前列腺切除术后中高危局限或局部晚期患者,早期挽救放疗策略可避免部分患者接受辅助放疗及其副作用。
  • 辅助放疗不应常规用于所有此类患者以改善无事件生存。

局限性

  • 长期结局数据尚未可用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is unclear whether adjuvant or early salvage radiotherapy following radical prostatectomy is more appropriate for men who present with localised or locally advanced prostate cancer. We aimed to prospectively plan a systematic review of randomised controlled trials (RCTs) comparing these radiotherapy approaches. METHODS: We used a prospective framework for adaptive meta-analysis (FAME), starting the review process while eligible trials were ongoing. RCTs were eligible if they aimed to compare immediate adjuvant radiotherapy versus early salvage radiotherapy, following radical prostatectomy in men (age ≥18 years) with intermediate-risk or high-risk, localised or locally advanced prostate cancer. We searched trial registers and conference proceedings until July 8, 2020, to identify eligible RCTs. By establishing the ARTISTIC collaboration with relevant trialists, we were able to anticipate when eligible trial results would emerge, and we developed and registered a protocol with PROSPERO before knowledge of the trial results (CRD42019132669). We used a harmonised definition of event-free survival, as the time from randomisation until the first evidence of either biochemical progression (prostate-specific antigen [PSA] ≥0·4 ng/mL and rising after completion of any postoperative radiotherapy), clinical or radiological progression, initiation of a non-trial treatment, death from prostate cancer, or a PSA level of at least 2·0 ng/mL at any time after randomisation. We predicted when we would have sufficient power to assess whether adjuvant radiotherapy was superior to early salvage radiotherapy. Investigators supplied results for event-free survival, both overall and within predefined patient subgroups. Hazard ratios (HRs) for the effects of radiotherapy timing on event-free survival and subgroup interactions were combined using fixed-effect meta-analysis. FINDINGS: We identified three eligible trials and were able to obtain updated results for event-free survival for 2153 patients recruited between November, 2007, and December, 2016. Median follow-up ranged from 60 months to 78 months, with a maximum follow-up of 132 months. 1075 patients were randomly assigned to receive adjuvant radiotherapy and 1078 to a policy of early salvage radiotherapy, of whom 421 (39·1%) had commenced treatment at the time of analysis. Patient characteristics were balanced within trials and overall. Median age was similar between trials at 64 or 65 years (with IQRs ranging from 59 to 68 years) across the three trials and most patients (1671 [77·6%]) had a Gleason score of 7. All trials were assessed as having low risk of bias. Based on 270 events, the meta-analysis showed no evidence that event-free survival was improved with adjuvant radiotherapy compared with early salvage radiotherapy (HR 0·95, 95% CI 0·75-1·21; p=0·70), with only a 1 percentage point (95% CI -2 to 3) change in 5-year event-free survival (89% vs 88%). Results were consistent across trials (heterogeneity p=0·18; I2=42%). INTERPRETATION: This collaborative and prospectively designed systematic review and meta-analysis suggests that adjuvant radiotherapy does not improve event-free survival in men with localised or locally advanced prostate cancer. Until data on long-term outcomes are available, early salvage treatment would seem the preferable treatment policy as it offers the opportunity to spare many men radiotherapy and its associated side-effects. FUNDING: UK Medical Research Council.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Vale CL, Fisher D, Kneebone A, et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet. 2020. PMID: 33002431. doi:10.1016/S0140-6736(20)31952-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。